Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetate

Catalog No. :
ACIPYD572
CAS No. :
2828447-02-3
Molecular Formula :
C14H20BNO4
Molecular Weight :
277.13

IUPAC Name:methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetate

Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$61.00Login to see priceInquiryInquiry
250mg95%$109.00Login to see priceInquiryInquiry
1g95%$295.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetate
IUPAC Namemethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetate
MDL No.MFCD18733859
Molecular FormulaC14H20BNO4
Molecular Weight277.13
SMILESO=C(OC)CC1=NC=CC=C1B2OC(C)(C)C(C)(C)O2
InChI KeyCOIRALZXGCGQFM-UHFFFAOYSA-N
Synonym2-Pyridineacetic acid, 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester
CAS No.2828447-02-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACIPYD572 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACCTHD361 route compound structure diagram
    ACCTHD361192642-95-8 In Stock
  4. Then
  5. ACIPYD572 route product structure diagram
    ACIPYD5722828447-02-3
Inquiry

2. ACIPYD572 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWLEF012 route compound structure diagram
    ACWLEF01276-09-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACIPYD572 route product structure diagram
    ACIPYD5722828447-02-3
Inquiry

Comments (0)